AM9928

Overview

AM9928 is a monoacylglycerol lipase ( MAGL ) inhibitor with IC 50 and K i values of 8.9 nM and 7.3 nM, respectively. AM9928 blocks the adhesion and migration of triple-negative breast cancer (TNBC) cells, and inhibits the secretion of IL-6 , IL-8 and VEGF-A by TNBC cells. AM9928 suppresses the activation of human brain microvascular endothelial cells (HBMECs) induced by TNBC-derived exosomes, and reduces the secretion of IL-8 and VEGF-A by HBMECs. AM9928 attenuates changes in blood-brain barrier permeability, inhibits tumor growth in the mammary fat pad, and reduces brain colonization of TNBC. AM9928 can be used in studies related to triple-negative breast cancer .

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Triple-Negative Breast Cancer | Products > Signaling Pathways > Cytoskeleton | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Exosomes | Products > Signaling Pathways > MAGL | Products > Signaling Pathways > Interleukin Related | Products > Signaling Pathways > VEGFR

Product Information

• Catalog No.: HY-182639
• CAS No.: 1869033-49-7
• Molecular Formula: C24H20N4O2
• Molecular Weight: 396.44
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source